Literature DB >> 9345421

Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis?

R Hohlfeld1.   

Abstract

Tumor necrosis factor (TNF)-alpha is a critical inflammatory mediator of experimental autoimmune encephalomyelitis and multiple sclerosis, and may therefore be a useful target for immunotherapy. Therapeutic strategies aimed at TNF include pharmacological inhibitors of TNF synthesis and/or processing and biological inhibitors of TNF effects. Several anti-TNF agents are currently being tested in multiple sclerosis in pilot clinical trials.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9345421     DOI： 10.1177/135245859600100619

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  4 in total

1.  Pathological findings in central nervous system demyelination associated with infliximab.

Authors:  Alicja Kalinowska-Lyszczarz; Mahboobeh Fereidan-Esfahani; Yong Guo; Claudia F Lucchinetti; W Oliver Tobin
Journal:  Mult Scler       Date:  2019-12-17       Impact factor: 6.312

2.  Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis.

Authors:  Laura Calza; Mercedes Fernandez; Alessandro Giuliani; Luigi Aloe; Luciana Giardino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 3.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

4.  Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure.

Authors:  Amy W Yu; Maggie Pecsok; Erin E Longbrake; Sarah F Wesley
Journal:  Neurol Clin Pract       Date:  2021-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.